Safeguarding the long-term health of hematopoietic stem cell donors: a continuous and evolving process to maintain donor safety and trust.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. The tumor microenvironment in leukemia: molecular pathways of immune evasion.Frontiers in immunology · 2026
   Review
2. Hematopoietic Stem Cell Donors' Experiences of Information and Side-Effects During the First Year After Donation-A Swedish National Study.Journal of clinical apheresis · 2025
   Article
3. Comparison between peripheral blood progenitor cell collection on the 4Blood transfusion = Trasfusione del sangue · 2023
   Article
4. Cell Reversal From a Differentiated to a Stem-Like State at Cancer Initiation.Frontiers in oncology · 2020
   Article
5. We have a specific duty to maximise the safety of related donors.Blood transfusion = Trasfusione del sangue · 2012
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as